Synlogic (NASDAQ: [[ticker:SYBX]]) has appointed Scott Plevy to serve as chief scientific officer. A gastroenterologist, Plevy was most recently a vice president in gastroenterology disease at Janssen Research & Development. Cambridge, MA-based Synlogic is developing drugs that employ engineered microbes to treat metabolic and inflammatory diseases, as well as cancer.
Author: Frank Vinluan
Xconomy Editor Frank Vinluan is a business journalist with experience covering technology and life sciences. Based in Raleigh, he was a staff writer at the Triangle Business Journal covering technology, biotechnology and energy before joining MedCityNews.com as North Carolina bureau chief. Prior to moving to North Carolina’s Research Triangle in 2007 he held business reporting positions at The Des Moines Register and The Seattle Times.
View all posts by Frank Vinluan
